Text Size
Trial record 11 of 314 for:    Cerebral Arteriosclerosis
Previous Study | Return to List | Next Study

Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients (OPERA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Medtronic
Information provided by (Responsible Party):
Associations for Establishment of Evidence in Interventions
ClinicalTrials.gov Identifier:
NCT01325935
First received: March 29, 2011
Last updated: August 17, 2012
Last verified: May 2011
History of Changes
  Purpose

A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent through noninferiority in the primary endpoint between two different continuous regimen (three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting stent in real-world Japanese patients and to examine the optimal duration of DAPT after stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should consist of consecutive patients undergoing DAPT for twelve months after stenting, while the short-term DAPT group (to be newly registered in the present clinical study) should consist of patients who are instructed to undergo DAPT for three months after stenting.


Condition Intervention Phase
Coronary Artery Disease
 Drug: Clopidogrel
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Associations for Establishment of Evidence in Interventions:

Primary Outcome Measures:
  • NACCE (Net adverse clinical and cerebral event) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    NACCE is defined as a composite endpoint consisting of death from some causes (including cardiac death and noncardiac death), myocardial infarction (Q-wave MI and non-Q wave MI), cerebral vascular accident, and major bleeding (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding).


Secondary Outcome Measures:
  • Stent thrombosis [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Incidence of stent thrombosis as per the definition by academic research council

  • MACE (major adverse cardiac events) [ Time Frame: 1, 3, 6, 9 and 12 months ] [ Designated as safety issue: Yes ]
    Incidence of MACE at months 1, 3, 6, 9, and 12 after stenting. MACE is defined as a composite endpoint consisting of cardiac death from some causes (including cardiac and noncardiac death), MI (Q-wave MI and non-Q wave MI), TLR, and coronary artery bypass graft (CABG).

  • TVR (target vessel revascularization) [ Time Frame: 9 and 12 months ] [ Designated as safety issue: Yes ]
    Incidence of target vessel revascularization at months 9 and 12 after stenting.

  • TLR (target lesion revascularization) [ Time Frame: 9 and 12 months ] [ Designated as safety issue: Yes ]
    Incidence of target lesion revascularization at months 9 and 12 after stenting.

  • DAPT compliance [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Duration of DAPT and patient compliance.

  • Hemorrhagic complications [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Incidence of hemorrhagic complications. (as per the modified version of REPLACE-2 criteria for bleeding and as per GUSTO criteria for bleeding)


Estimated Enrollment: 2400
Study Start Date: April 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Short-term DAPT group
1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
 Drug: Clopidogrel
DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
No Intervention: Long-term DAPT group
1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)

  Eligibility

Ages Eligible for Study:   20 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical inclusion criteria

    • Patient over age 20 years.
    • Patient who is clinically indicated for PCI by stenting at least in one coronary lesion that is visually confirmed by coronary angiography.
    • Patient who has agreed to conditions after receiving an explanation about the contents of the present clinical study and who has signed the consent form approved by the ethical review board at each study site.
    • Patient who has agreed to undergo all clinical FUs listed in the present protocol.

  2. Coronary angiographic inclusion criteria:

    • Patient who has a > 50% occlusion or stenosis that is visually confirmed by coronary angiography in a native coronary artery > 2.5 mm in diameter and in whom the relevant coronary artery has an anatomical structure that is eligible for PCI with Endeavor Zotarolimus-eluting stent.

Exclusion Criteria:

  1. Clinical exclusion criteria

    • Patient over age 85 years.
    • Patient with ST elevation MI who requires primary or rescue PCI and whose performance status falls under any of the exclusion criteria.
    • Patient with cardiogenic shock.
    • Patient who underwent stent treatment with BMS in other lesions within 6 months prior to the conduct of index PCI of the target vessel.
    • Patient who has undergone some treatment with DES for coronary lesions.
    • Patient who is scheduled to undergo elective surgery within 12 months after index PCI.
    • Patient whose left ventricular ejection fraction (LVEF) is < 40%.
    • Patient with a hemorrhagic predisposition or a history of coagulation abnormality
    • Patient in whom the total number of deployed stents exceeds 4,regardless of the number of lesions and the number of affected branches.
    • Patient with a verified history of CVA before stenting.
    • Patient with a verified history of active peptic ulcer or upper gastrointestinal tract bleeding before Stenting.
    • Patient showing impaired renal function. (serum creatinine concentration: > 1.8 mg/dL)
    • Patient with known contraindications for aspirin or clopidogrel. (the physician should assess tolerability within the range of routine medical care)
    • Patient with a known disorder who has a life expectancy of less than 12 months.
    • Patient who is incompetent to adhere to all clinical FUs listed in the present protocol.

  2. Angiographic exclusion criteria:

    • Lesions located within the saphenous venin graft (SVG).
    • Unprotected lesions in the left coronary trunk.
    • Lesions of in-stent restenosis in previously deployed DES or BMS.
    • Lesions with an anatomical structure of the coronary artery that is not eligible for treatment by the deployment of Endeavor ZES.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325935

  Show 112 Study Locations
Sponsors and Collaborators
Associations for Establishment of Evidence in Interventions
Medtronic
Investigators
Principal Investigator: Takaaki Isshiki, M.D. Teikyo University
Principal Investigator: Shinsuke Nanto, M.D. Osaka University
Principal Investigator: Masato Nakamura, M.D. Toho University Ohashi Medical Center
  More Information

No publications provided

Responsible Party: Associations for Establishment of Evidence in Interventions
ClinicalTrials.gov Identifier: NCT01325935     History of Changes
Other Study ID Numbers: OPERA 1.0 - AEEI
Study First Received: March 29, 2011
Last Updated: August 17, 2012
Health Authority: Japan: Institutional Review Board

Keywords provided by Associations for Establishment of Evidence in Interventions:
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Disease
Cardiovascular Disease
 Arteriosclerosis
Arterial Occlusive Disease
Vascular Disease
Clopidogrel
Platelet Aggregation Inhibitors

Additional relevant MeSH terms:
Arteriosclerosis
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Clopidogrel
Platelet Aggregation Inhibitors
 Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 18, 2013